The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Combination of antiangiogenic therapy using the mTOR inhibitor RAD001 (everolimus) and low-dose chemotherapy for locally advanced and/or metastatic pancreatic cancer: Dose-finding study.
Mareile Joka
No relevant relationships to disclose
Stefan Hubert Boeck
No relevant relationships to disclose
Christian Hosius
No relevant relationships to disclose
Laetitia Decroix
No relevant relationships to disclose
Christoph May
No relevant relationships to disclose
Barbara Alberter
No relevant relationships to disclose
Anette Pustowka
No relevant relationships to disclose
Volker Heinemann
No relevant relationships to disclose
Christiane Bruns
No relevant relationships to disclose